

Table of Contents

Year ended March 31, 2021

	Page
Independent Auditors' Report	
Financial Statements:	
Statement of Financial Position	1
Statement of Operations	2
Statement of Changes in Net Assets	3
Statement of Cash Flows	4
Statement of Remeasurement Gains and Losses	5
Notes to Financial Statements	6
Schedule A - Other Funded Programs	27



KPMG LLP 150 Elgin Street, Suite 1800 Ottawa ON K2P 2P8 Canada Telephone 613-212-5764 Fax 613-212-2896

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of the Children's Hospital of Eastern Ontario - Ottawa Children's Treatment Centre

Opinion

We have audited the financial statements of the Children's Hospital of Eastern Ontario - Ottawa Children's Treatment Centre (the "Entity"), which comprise:

- the statement of financial position as at March 31, 2021
- the statement of operations for the year then ended
- the statement of changes in net assets for the year then ended
- the statement of cash flows for the year then ended
- the statement of remeasurement gains and losses for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2021, and its results of operations, its changes in net assets, its cash flows and its remeasurement gains and losses for the year then ended in accordance with Canadian public sector accounting standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "*Auditors' Responsibilities for the Audit of the Financial Statements*" section of our auditors' report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other responsibilities in accordance with these ethical requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Page 2

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian public sector accounting standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

 Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



Page 3

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

KPMG LLP

Chartered Professional Accountants, Licensed Public Accountants Ottawa, Canada June 10, 2021

Statement of Financial Position

March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

		2021		2020
Assets				
Current assets:				
Cash	\$	20,853	\$	21,209
Accounts receivable (note 3)		34,260		17,380
Inventories		3,610		4,189
Prepaid expenses		6,124		5,589
Current portion of due from related parties (note 5)		2,597		5,631
		67,444		53,998
Due from related parties (note 5)		595		1,546
Designated investments (note 6)		8,988		5,785
Funds held for others (notes 6 and 11)		8,743		8,038
Capital assets (note 7)		162,443		167,640
	\$	248,213	\$	237,007
Liabilities and Net Assets				
Current liabilities:				
Accounts payable and accrued liabilities (note 4)	\$	41,242	\$	40,867
Due to related parties (note 8)	Ψ	527	Ψ	
Current portion of long-term debt (note 12)		3,288		3,187
Current portion of deferred contributions (note 9)		18,355		13,858
`		63,412		57,912
Deferred contributions (note 9)		10,853		9,142
Deferred contributions for capital assets (note 10)		108,557		107,459
Funds held for others (note 11)		8,743		8,038
Long-term debt (note 12)		17,580		20,868
Accrued benefit liability (note 13)		7,153		6,626
Interest rate swap liability (note 12)		327		784
		216,625		210,829
Net assets:				
Invested in capital assets (note 14)		33,018		36,126
Unrestricted deficiency		(1,103)		(9,164)
Accumulated remeasurement losses		(327)		(784)
		31,588		26,178
Contingent liabilities and commitments (note 15)				
	\$	248,213	\$	237,007
See accompanying notes to financial statements.			2021.0	ned by 6.08 Director

1

Statement of Operations

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

		2021	2020
Revenue:			
Ministry of Health (MOH)/Ontario Health (OH)	\$	191,379	\$ 164,900
Patient services	,	43,504	48,548
Other operating revenues and recoveries		31,632	33,509
Amortization of deferred contributions for equipment		5,857	5,921
Other funded programs (Schedule A)		67,745	66,540
		340,117	319,418
Expenses:			
Salaries and benefits		179,776	164,764
Medical staff remuneration		9,486	9,985
Supplies and other expenses		42,553	41,642
Medical and surgical supplies		15,663	16,836
Drugs and medical gases		10,034	7,679
Amortization - equipment		11,866	11,143
Other funded programs (Schedule A)		67,745	66,540
		337,123	318,589
Excess of revenue over expenses before			
the undernoted items and non-recurring item		2,994	829
Amortization of deferred contributions for buildings		3,745	3,669
Amortization of buildings		(5,309)	(5,174)
		(1,564)	(1,505)
Excess of revenue over expenses before			
the non-recurring item		1,430	(676)
Non-recurring working capital funding (note 20)		3,523	-
Excess (deficiency) of revenue over expenses	\$	4,953	\$ (676)

Statement of Changes in Net Assets

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

	In	vested in			2021	2020
	capi	tal assets	Un	restricted	Total	Total
Balance, beginning of year	\$	36,126	\$	(9,164)	\$ 26,962	\$ 27,638
Excess (deficiency) of revenue						
over expenses		_		4,953	4,953	(676)
Net purchases of capital assets		11,978		(11,978)	_	-
Amortization of capital assets		(17,175)		17,175	_	-
Decrease in long-term debt		3,187		(3,187)	_	-
Deferred contributions for capital assets		(10,700)		10,700	_	_
Amortization of deferred contributions for capital assets		9,602		(9,602)	-	_
Balance, end of year	\$	33,018	\$	(1,103)	\$ 31,915	\$ 26,962

Statement of Cash Flows

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

		2021		2020
Cash provided by (used in):				
Operating activities:				
Excess (deficiency) of revenue over expenses	9	6 4,953	\$	(676)
Items not affecting cash:				
Amortization:				
Capital assets		17,175		16,317
Deferred contributions for capital assets		(9,602)		(9,590)
Increase in actuarial valuation of accrued		004		700
employee future benefits		804		783
Employee future benefits paid		(277)		(375)
Increase in deferred contributions		6,208		5,161
		19,261		11,620
Change in non-cash operating working capital:		(40.000)		(, , , , , , , , , , , , , , , , , , ,
Accounts receivable		(16,880)		(4,148)
Due to/from related parties		4,512		(290)
Inventories		579		(1,588)
Prepaid expenses		(535)		(1,288)
Accounts payable and accrued liabilities		500		(168)
		7,437		4,138
Investing activities:				
Net purchases of capital assets		(11,978)		(13,487)
Net withdrawals (acquisitions) of designated investments		(3,203)		3,401
		(15,181)		(10,086)
Financing activities:				
Net repayment of long-term debt		(3,187)		(3,068)
Deferred contributions for capital assets		10,700		8,484
Changes in accounts payable for construction		(125)		92
		7,388		5,508
Decrease in cash		(356)		(440)
		<u> </u>		(-)
Cash, beginning of year		21,209		21,649
Cash, end of year	\$	20,853	\$	21,209
Interest paid	\$	478	\$	572
	Ψ		Ψ	0.2

Statement of Remeasurement Gains and Losses

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

	2021	2020
Accumulated remeasurement gains (losses), beginning of year	\$ (784)	\$ 79
Unrealized losses attributable to: Interest rate swaps	457	(863)
Accumulated remeasurement losses, end of year	\$ (327)	\$ (784)

Notes to Financial Statements

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

1. Description:

The Children's Hospital of Eastern Ontario - Ottawa Children's Treatment Centre (CHEO) is incorporated under the Ontario Corporations Act. CHEO provides health care services to children in Eastern Ontario, Western Quebec and Nunavut. CHEO is a registered charity and as such is not subject to income tax under Paragraph 149(1)(f) of the Income Tax Act (Canada).

2. Significant accounting policies:

The financial statements have been prepared by management in accordance with Canadian Public Sector Accounting Standards including the 4200 standards for government not-for-profit organizations and include the following significant accounting policies.

(a) Revenue recognition:

Operating grants are recorded as revenue in the period to which they relate. Where a portion of a grant relates to a future period, it is deferred and recognized in that subsequent period. Grants approved but not received at the end of an accounting period are accrued.

Revenue from other provinces and uninsured patients, operational revenue, and ancillary services are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

CHEO follows the deferral method of accounting for contributions for not-for-profit organizations which includes provincial government allocations, other contributions and grants.

Externally restricted contributions are recognized as revenue in the year in which the conditions for the restriction have been met. Contributions restricted for the purchase of capital assets are deferred and amortized into revenue on a straight-line basis, at a rate corresponding with the amortization rate for the related capital assets.

Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

(b) Funding policy:

Under the current funding policy, CHEO is essentially funded on a fixed global-budget base. CHEO is allowed to retain any excess of revenue over expenses derived from its operations and, conversely, retains responsibility for any deficit it may incur.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

2. Significant accounting policies (continued):

(c) Donated services:

A substantial number of volunteers contribute a significant amount of their time each year to CHEO. Owing to the difficulty in assessing the number of hours and the fair value thereof, contributed services are not recognized in the financial statements.

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Derivative instruments that are quoted in an active market are reported at fair value. All other financial instruments are subsequently recorded at cost or amortized cost unless management has elected to carry the instruments at fair value. Management has elected to record all investments at fair value as they are managed and evaluated on a fair value basis.

Unrealized changes in fair value of designated investments are recorded in deferred contributions and funds held for others.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

All financial assets are assessed for impairment on an annual basis. When a decline is determined to be other than temporary, the amount of the loss is reported in the statement of operations.

Canadian public sector accounting standards require CHEO to classify fair value measurements using a fair value hierarchy, which includes three levels of information that may be used to measure fair value:

- Level 1 Unadjusted quoted market prices in active markets for identical assets or liabilities;
- Level 2 Observable or corroborated inputs, other than level 1, such as quoted prices for similar assets or liabilities in inactive markets or market data for substantially the full term of the assets or liabilities; and
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

2. Significant accounting policies (continued):

(d) Financial instruments (continued):

CHEO uses derivative financial instruments to manage interest rate risk. The only derivative products used are interest rate swaps (see notes 11 and 16 for further details). Derivative instruments are recorded on the statement of financial position as assets or liabilities and are measured at fair value. Derivatives with positive fair value are reported as assets and derivatives with negative fair value are reported as liabilities.

CHEO uses hedge interest rate swaps to hedge variability in forecasted cash flows. Changes in the fair value of the swap are included directly in the statement of remeasurement gains and losses.

The periodic exchanges of payments on interest rate swaps designated as hedges of debt are recorded as an adjustment to interest expenses of the hedged item in the same period.

The fair values of over-the-counter derivatives are based on prevailing market rates for instruments with similar characteristics and maturities, net present value analysis, or are determined by using pricing models that incorporate current market and contractual prices of the underlying instruments, time value of money, yield curve and volatility factors. Counterparty credit risk and liquidity valuation adjustments are recorded, as appropriate.

(e) Inventories:

Inventories are valued at lower of cost on a moving-average basis and current replacement cost. Major components of inventory include drugs and medical and surgical supplies.

(f) Capital assets:

Capital assets are recorded at cost. Assets acquired by a capital lease are amortized over the estimated life of the assets or over the lease term, as appropriate. When a capital asset no longer contributes to CHEO's ability to provide services, its carrying amount is written down to its residual value. Amortization is provided on the straight-line basis over the estimated useful lives as follows:

Asset	Useful life
Land improvements	10 to 25 years
	according to the class of improvements
Buildings	15 to 50 years
Major equipment	according to the class of the asset 5 to 15 years
	according to the class of the asset
Minor equipment	Minor equipment is expensed as incurred

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

2. Significant accounting policies (continued):

(f) Capital assets (continued):

The cost of capital projects in progress will be transferred to the cost of buildings and/or major equipment and begin to be amortized when construction/implementation is complete and the facility/equipment is put in use. Land is not amortized due to its infinite life.

(g) Long-term lease agreements:

CHEO has long-term lease agreements with third parties for buildings that have been constructed on lands owned by CHEO. These land leases are accounted for by CHEO as operating leases. The buildings which were constructed by third parties are not accounted for as assets of CHEO and any assets or related liabilities thereon would be accounted for by CHEO upon termination of the lease agreement.

(h) Employee future benefits:

CHEO provides defined retirement and other future benefits for substantially all retirees and employees. These future benefits include life insurance and health care benefits.

CHEO accrues its obligations under the defined benefit plans as the employees render the services necessary to earn the other retirement benefits. The actuarial determination of the accrued benefit obligations for other retirement benefits uses the projected benefit method prorated on service (which incorporates management's best estimate of future salary levels, other cost escalation, retirement ages of employees and other actuarial factors).

The most recent actuarial valuation of the benefit plans for funding purposes was as of March 31, 2019, and the next required valuation will be as of March 31, 2022.

Actuarial gains (losses) on plan assets arise from the difference between the actual return on plan assets for a period and the expected return on plan assets for that period. Actuarial gains (losses) on the accrued benefit obligation arise from differences between actual and expected experience and from changes in the actuarial assumptions used to determine the accrued benefit obligation. The net accumulated actuarial gains (losses) are amortized over the average remaining service period of active employees. These defined benefit plans are not funded.

The average remaining service period of active employees covered by the employee benefit plans is 14.0 years (2020 - 14.0 years).

Past service costs arising from plan amendments are recognized immediately in the period the plan amendments occur.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

2. Significant accounting policies (continued):

(h) Employee future benefits (continued):

CHEO is an employer member of the Healthcare of Ontario Pension Plan, which is a multiemployer, defined benefit pension plan. CHEO has adopted defined contribution plan accounting principles for this Plan because insufficient information is available to apply defined benefit plan accounting principles.

(i) Use of estimates:

The preparation of financial statements in conformity with Public Sector Accounting Standards requires management to make estimates that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. In particular, the assumptions underlying the employee future benefit calculations contain significant estimates. Actual results could differ from these estimates. These estimates are reviewed annually and as adjustments become necessary, they are recorded in the financial statements in the period they become known.

3. Accounts receivable:

	2021	2020
MOH / OH MCCSS Patient services External organizations Harmonized sales tax	\$ 18,225 174 8,221 5,825 1,815	\$ 4,139 90 5,942 4,999 2,210
	\$ 34,260	\$ 17,380

4. Accounts payable and accrued liabilities:

	2021	2020
MOH / OH MCCSS External organizations Government remittances	\$ 5,981 426 31,676 3,159	\$ 1,601 636 35,840 2,790
	\$ 41,242	\$ 40,867

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

5. Due from related parties:

	2021	2020
EORLA - prime less 0.25% variable rate promissory note with principal payments of \$866,094 annually, maturing March 2022	\$ 866	\$ 1,732
CHEO Research Institute - interest free loan with principal payments of \$85,000 annually, maturing March 2029	680	765
CHEO Research Institute – non-interest-bearing receivable with no defined terms of repayment	_	692
CHEO Foundation - non-interest-bearing receivable with no defined terms of repayment	1,646	3,988
	3,192	7,177
Less: current portion of due from related parties	(2,597)	(5,631)
Long-term portion	\$ 595	\$ 1,546

6. Designated investment and funds held for others:

	Fair value	Cost	2021 Fair value
Cash	\$ 6	\$ 6	0.0%
Short-term investments	13,478	13,495	76.0%
Provincial bonds	1,067	1,043	6.0%
Corporate bonds	3,180	3,141	18.0%
	\$ 17,731	\$ 17,685	100.0%

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

6. Designated investment and funds held for others (continued):

	Fair value	Cost	2020 Fair value
Cash Short-term investments Provincial bonds Corporate bonds	\$ 6 6,376 1,564 5,877	\$ 6 6,344 1,547 5,896	0.0% 46.1% 11.3% 42.6%
	\$ 13,823	\$ 13,793	100.0%

Bonds are debt obligations of governments and corporate entities paying interest at rates appropriate to the market at their date of purchase. The bonds mature at face value on a staggered basis until 2026. Interest rates for these securities range from 1.00% to 3.00% (2020 - 1.25% to 4.20%).

These investments can be liquidated by CHEO on demand.

7. Capital assets:

Capital assets consist of:

	Acc Cost an				2021 Net book value	
Land	\$	454	\$	_	\$ 454	
Land improvement		2,115		1,313	802	
Buildings		173,658		70,295	103,363	
Major equipment		220,611		165,913	54,698	
Projects in progress		3,126		_	3,126	
	\$	399,964	\$	237,521	\$ 162,443	

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

7. Capital assets (continued):

	Accumulated Cost amortization							
Land Land improvement Buildings Major equipment Projects in progress	\$	454 2,115 171,085 212,202 2,130	\$		\$	454 910 106,053 58,093 2,130		
	\$	387,986	\$	220,346	\$	167,640		

Cost and accumulated amortization are presented net of disposals of \$Nil (2020 - \$Nil).

8. Due to related parties:

The amount due to CHEO Research Institute does not have defined terms of repayment and is non-interest bearing. The amount is recorded at the exchange amount.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

9. Deferred contributions:

Changes in the deferred contributions balance are as follows:

	Capital	Other	2021 Total
	funds	Other	Total
Balance, beginning of year Add: amount received during the year	\$ 9,142 2,932	\$ 13,858 5,255	\$ 23,000 8,187
Add: change in unrealized losses on designated investments Less: amount transferred to deferred	4	6	10
contributions for capital assets Less: amount recognized as revenue	(1,634)	_	(1,634)
during the year	_	(355)	(355)
Transfers	409	(409)	· - /
Balance, end of year	\$ 10,853	\$ 18,355	\$ 29,208
Accumulated unrealized gains (losses) on			
designated investments, beginning of year	\$ (4)	\$ 23	\$ 19
Accumulated unrealized gains on			
designated investments, end of year	\$ _	\$ 29	\$ 29

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

9. Deferred contributions (continued):

	Capital funds	Other	2020 Total
Balance, beginning of year Add: amount received during the year Add: change in unrealized losses on	\$ 7,843 1,302	\$ 9,996 4,839	\$ 17,839 6,141
designated investments Less: amount transferred to deferred	17	29	46
contributions for capital assets Less: amount recognized as revenue	(983)	_	(983)
during the year Transfers	_ 963	(43) (963)	(43)
Balance, end of year	\$ 9,142	\$ 13,858	\$ 23,000
Accumulated unrealized losses on designated investments, beginning of year	\$ (21)	\$ (6)	\$ (27)
Accumulated unrealized gains (losses) on designated investments, end of year	\$ (4)	\$ 23	\$ 19

The deferred contribution balance of \$10,853,344 (2020 - \$9,142,105) in the Capital Funds component represents capital grants from the Province of Ontario and contributions from the CHEO Foundation for capital equipment. As these funds are spent on equipment, a corresponding amount is transferred to deferred contributions for capital assets.

10. Deferred contributions for capital assets:

Changes in the deferred contributions for capital assets are as follows:

	2021	2020
Balance, beginning of year Add: amount received during the year Add: amount transferred from deferred contributions Add: amount contributed by the CHEO Foundation Less: amount recognized as revenue during the year	\$ 107,459 5,378 409 4,913 (9,602)	\$ 108,565 4,248 555 3,681 (9,590)
Balance, end of year	\$ 108,557	\$ 107,459

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

11. Funds held for others:

During the year, CHEO was involved with the administration of several projects. As administrator of these projects, CHEO has accepted the responsibility of collecting funds from supporters and issuing cheques for approved expenses. The receipts and disbursements for the projects are not recognized as revenues and expenses of CHEO. The related assets are disclosed in note 6.

	2021	2020
Balance, beginning of year Add: amount received during the year Add: change in unrealized gains on investments Less: amounts disbursed during the year	\$ 8,038 3,431 6 (2,732)	\$ 9,284 3,737 20 (5,003)
Balance, end of year	\$ 8,743	\$ 8,038
Accumulated unrealized gains (losses) on investments, beginning of year	\$ 12	\$ (8)
Accumulated unrealized gains on investments, end of year	\$ 18	\$ 12

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

12. Long-term debt and credit facilities:

(a) Long-term debt:

	2021	2020
3.33% fixed rate loan with principal payments of \$35,115 monthly including interest, maturing November 2023	\$ 1,074	\$ 1,453
2.83% fixed rate loan with principal payments of \$25,000 monthly, maturing October 2024	1,075	1,375
3.70% fixed rate loan with principal payments of \$28,446 monthly including interest, maturing November 2024	1,167	1,459
CDOR plus 0.40% stamping fee Banker's Acceptance fixed by interest rate swap with interest only payments until March 2018, maturing March 2029	17,552	19,768
	20,868	24,055
Less: current portion of long-term debt	(3,288)	(3,187)
Long-term portion	\$ 17,580	\$ 20,868

The estimated fair value of the loans are \$1,097,966, \$1,033,931, \$1,209,658 and \$17,195,028 (2020 - \$1,494,626, \$1,302,333, \$1,507,332 and \$18,381,855) based on a quoted market rates as at March 31, 2021 of 1.69%, 2.14%, 1.83% and 2.34% respectively (2020 - 1.78%, 2.35%, 2.35% and 1.74%, respectively).

Principal payments required over the next five years are as follows:

2021/22 2022/23 2023/24 2024/25 2025/26	\$ 3,288 3,199 3,083 2,579 2,179
	\$ 14,328

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

12. Long-term debt and credit facilities (continued):

(b) Credit facilities:

CHEO has an operating credit facility which allows it to borrow up to \$7,000,000 at an interest rate of prime less 0.25%. The balance of amounts borrowed as at March 31, 2021 is \$Nil (2020 - \$Nil).

CHEO has a revolving credit facility which allows it to borrow up to \$10,000,000 for the purposes of acquiring capital assets. The term and rate associated with any loan taken against the facility are determined at the time that the funds are drawn. The balance of the two loans outstanding under this facility as at March 31, 2021 is \$2,241,993 (2020 - \$2,834,259).

(c) Interest rate swaps:

Interest rate swaps are agreements where two counterparties exchange a series of payments based on different interest rates applied to a notional amount in a single currency. Interest rate swaps are used to adjust exposure to interest rate risk by modifying the repricing or maturity characteristics of existing and/or anticipated assets and liabilities.

CHEO has entered into an interest rate swap agreement to manage the volatility of interest rates associated with debt related to systems acquisitions. CHEO has converted a net notional \$24 million of floating rate long-term debt to a fixed rate of 1.86%. The maturity date of the interest rate swap is March 1, 2029.

The interest rate swaps have unrealized accumulated remeasurement losses of \$327,468 (2020 - losses of \$783,836), which are recorded on the statement of financial position as at March 31, 2021. The current year impact of the change in fair value of the interest rate swap is a decrease of accumulated remeasurement gains of \$456,568 (2020 - \$862,902).

The fair value of the interest rate swap has been determined using Level 2 of the fair value hierarchy. The fair value of the interest rate swap is based on underlying market yield curves and risk premiums. These inputs are discounted to estimate the future cash flows of the variable and fixed legs of the instrument.

13. Accrued employee future benefits:

CHEO offers defined benefit plans which provide pension and other post-retirement benefits to most of its employees. The measurement date used to determine the accrued benefit obligation is March 31, 2021. The most recent actuarial valuation of employee future benefits for accounting purposes was completed as at March 31, 2021.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

13. Accrued employee future benefits (continued):

The liability associated with the post-retirement and post-employment plans as at March 31, 2021 is as follows:

	20	21	2020
Accrued benefit obligation: Balance, beginning of year Current benefit cost Interest Benefits paid	2	49 \$ 84 66 77)	8,101 365 258 (375)
Balance, end of year	8,7	22	8,349
Unamortized actuarial losses	(1,6	79)	(1,833)
EORLA accrued benefit	1	10	110
Employee future benefits liability	\$ 7,1	53 \$	6,626

CHEO entered into a formal arrangement with the Eastern Ontario Regional Laboratory Association (EORLA) to transfer all laboratory operations to EORLA. Effective April 1, 2012, 78 of CHEO's non-medical laboratory employees became employees of EORLA, of which 52 employees are members of the benefit plan. As a result, the pension plan for these employees was curtailed and the liability for EORLA's employees separated from CHEO's accrued benefit liability. The EORLA liability of \$110,400 (2020 - \$110,400) as at March 31, 2021 will be reduced as benefits are paid out to former employees of CHEO.

The significant actuarial assumptions adopted in measuring the accrued benefit obligation as at March 31, 2021 are as follows:

	2021	2020				
Discount rate	3.18%	3.18%				
Medical inflation	6.42% for year ended March 31, 2020 reducing b per year to an ultimate rate o					
Dental inflation	3.75%	3.75%				
Mortality	Uninsured pensioner 1994 mortality rates with mortality improvements projected to 2030					

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

13. Accrued employee future benefits (continued):

Healthcare of Ontario Pension Plan:

Substantially all of the employees of CHEO are eligible to be members of the Hospitals of Ontario Pension Plan (the "Plan"). The Plan is a multi-employer, defined benefit pension plan. The Plan is accounted for as a defined contribution plan. Employer contributions to the Plan during the year by CHEO amounted to \$15,154,977 (2020 - \$14,496,160). These amounts are included as operating expenses.

In consultation with its actuaries, pension expense is based on the Plan management's best estimates, of the amount required to provide a high level of assurance that benefits will be fully represented by fund assets at retirement, as provided by the Plan. The funding objective is for employer contributions to the Plan to remain a constant percentage of employees' contributions.

Variances between actuarial funding estimates and actual experience may be material and any differences are generally to be funded by the participating members. The most recent actuarial valuation of the Plan as at December 31, 2020 indicates the plan is fully funded.

14. Net assets invested in capital assets:

Investment in capital assets is calculated as follows:

	2021	2020
Capital assets Amounts financed by:	\$ 162,443	\$ 167,640
Deferred contributions for capital assets Long-term debt	(108,557) (20,868)	(107,459) (24,055)
	\$ 33,018	\$ 36,126

CHEO receives contributions restricted in use from various sources and has complied with the conditions and requirements of capital grants, contributions and long-term debt throughout the year.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

15. Contingent liabilities and commitments:

- (a) As a member of the Ottawa Health Sciences Centre Inc., CHEO is party to a Thermal Energy Agreement (TEA) with TransAlta Corporation for the purchase of thermal energy for heating and humidifying the hospital premises. In 2009, the TEA was re-negotiated and resulted in a ten-year extension of its term from January 1, 2013 to January 1, 2024. The revised TEA, which was retroactive to January 1, 2007, stipulates a minimum Take or Pay quantity of steam and medium temperature hot water each year until the expiry of the contract and also provides for a new surcharge levy of \$2.22/gigajoule to facilitate the expansion of the TransAlta plant to meet future site thermal demands.
- (b) CHEO is also committed under supplier contracts to purchase services for the next five years for a total amount of \$18,343,210 (2020 \$15,299,436).
- (c) From time to time, CHEO is a party to claims related to its operations, the majority of which are covered under CHEO's insurance policy. No provision has been made for loss in these financial statements as, in management's opinion, these claims will not have a material adverse effect on its financial position or result of operations.
- (d) CHEO is a member of the Healthcare Insurance Reciprocal of Canada (HIROC), which is a pooling of the liability insurance risks of its members. Members of the pool pay annual premiums that are actuarially determined. HIROC members are subject to reassessment for losses, if any, experienced by the pool for the years in which they are members and these losses could be material. No reassessments have been made at March 31, 2021.

16. Related entities:

CHEO is related to the following entities: Children's Hospital of Eastern Ontario Foundation, Children's Hospital of Eastern Ontario Research Institute Inc., Eastern Ontario Regional Laboratory Association and Ottawa Regional Hospital Linen Services by virtue of representation on their Boards or other forms of influence. CHEO does not have control of these entities and the net assets and results of operations of these entities are not included in CHEO's financial statements. In addition to the related party transactions disclosed elsewhere in these financial statements, CHEO has entered into the following transactions with these entities:

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

16. Related entities (continued):

Children's Hospital of Eastern Ontario Foundation (Foundation)

During the year, CHEO received total contributions from the Foundation in the amount of \$12,723,380 (2020 - \$12,968,102) allocated as follows: operating contributions \$1,952,235 (2020 - \$1,886,155), capital contributions \$3,998,649 (2020 - \$4,524,309) and other special purpose funds in the amount of \$6,772,496 (2020 - \$6,557,638). Special purpose funds are not included as a revenue or an expense to CHEO. The Foundation is a tax-exempt charitable entity created without share capital under the laws of Ontario.

Children's Hospital of Eastern Ontario Research Institute (Institute)

CHEO provides administrative services, including financial accounting, human resources, material management and information services, to the Institute for a total annual fee of \$395,500 (2020 - \$395,500). All operating and capital expenses of the Institute are initially paid by CHEO. Costs related to building infrastructure and support, as well as insurance coverage, are billed back to the Institute on a cost recovery basis. During the year, CHEO provided funds to the Institute in the amount of \$301,300 (2020 - \$301,300) as a contribution towards operating costs. The Institute is a tax-exempt charitable entity created without share capital under the Canada Not-for-Profit Corporations Act.

Eastern Ontario Regional Laboratory Association (EORLA)

CHEO is a founding member of EORLA which was established to provide laboratory services to member hospitals on a cost of service basis. EORLA is incorporated without share capital under the Ontario Business Corporations Act. EORLA is a not-for-profit organization under the Income Tax Act and as such is exempt from income taxes. Effective April 1, 2013, CHEO entered into a formal arrangement with EORLA to transfer all laboratory operations (except Genetics) to EORLA. All existing laboratory equipment remains the property of CHEO and will be leased to EORLA at no charge. New equipment will be acquired directly by EORLA as the need arises. Included in CHEO's accounts receivable at March 31, 2021 is a receivable of \$51,755 (2020 - \$37,434) for costs incurred by CHEO on behalf of EORLA. During the year, CHEO paid \$8,553,360 (2020 - \$8,723,520) for laboratory services provided by EORLA. As at March 31, 2021 CHEO had a receivable of \$431,926 (2020 - payable of \$210,026) related to these services.

Recovery of prior year's laboratory costs:

In April 2016, EORLA determined it overcharged members for tests performed at the CHEO reference lab over a four-year period. CHEO was overbilled a total of \$5,300,000 during this time. EORLA members have agreed to a six-year repayment plan. The amount owing of \$866,093 (2020 - \$1,732,187) is included in due from related parties.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

16. Related entities (continued):

Ottawa Regional Hospital Linen Services (ORHLS)

CHEO is a founding member ORHLS. ORHLS was established to provide laundry services for the member hospitals on a cost of service basis. ORHLS is incorporated without share capital under the Ontario Business Corporations Act and is a not-for-profit organization under the Income Tax Act (Canada) and as such is exempt from income taxes. As at March 31, 2021, CHEO had an economic interest of \$1,059,552 (2020 - \$718,734) of total net assets of \$14 513 689(2020 - \$10,372,709). For the year ended March 31, 2021, CHEO paid \$1,322,079 (2020 - \$1,120,973) to ORHLS for laundry services.

17. Financial instruments:

The fair value of CHEO's accounts receivable, accounts payable and accrued liabilities approximates cost due to their short-term nature. The fair value of investments is described in note 6 and the fair value of debt in note 11.

The following table presents the investments recorded at fair value in the statement of financial position, classified using the fair value hierarchy described above:

								2021
		Level 1		Level 2		Level 3		Total
Cash	\$	6	\$	_	\$	_	\$	6
Short-term investments	Ŧ	13,478	Ŧ	_	Ŧ	_	Ŧ	13,478
Provincial bonds		,		1,067		_		1,067
Corporate bonds		_		3,180		_		3,180
Interest rate swap		-		(327)		-		(327)
	\$	13,484	\$	3,920	\$	_	\$	17,404
								2020
		Level 1		Level 2		Level 3		Total
Cash	\$	6	\$	_	\$	_	\$	6
Short-term investments	Ŧ	6,376	Ŧ	_	Ŧ	_	Ŧ	6,376
Provincial bonds		,		1,564		_		1,564
Corporate bonds		_		5,877		_		5,877
Interest rate swap		-		(784)		-		(784)
	\$	6,382	\$	6,657	\$	_	\$	13,039

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

17. Financial instruments (continued):

Financial risk factors

CHEO's activities expose it to a variety of financial risks: market risk (including interest rate, currency (foreign exchange), and other price risks), credit risk and liquidity risk. Investments are held for liquidity purposes, or for longer terms, to achieve the highest possible rate of return consistent with the investment policies approved by the Board of Directors.

(a) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss. CHEO is exposed to this risk relating to its cash and accounts receivable. CHEO holds its cash accounts with federally regulated chartered banks who are insured by the Canadian Deposit Insurance Corporation.

CHEO's receivables are with governments, government funding agencies, patients and residents and corporate entities. CHEO believes that these receivables do not have significant credit risk in excess of allowances for doubtful accounts that have been established. The balance of the allowance for doubtful accounts at March 31, 2021 is \$1,654,804 (2020 - \$1,403,109).

(b) Liquidity risk:

Liquidity risk is the risk that CHEO will be unable to fulfill its obligations on a timely basis or at a reasonable cost. CHEO manages its liquidity risk by monitoring its operating requirements. CHEO prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

Accounts payable and accrued liabilities are generally due within 30 days of receipt of an invoice.

(c) Market risk:

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of market factors. Market factors include three types of risk: currency risk, interest rate risk and other price risk.

(i) Currency risk:

CHEO believes it is not subject to significant foreign currency risk arising from its financial instruments.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

17. Financial instruments (continued):

- (c) Market risk (continued):
 - (ii) Interest rate risk:

Interest rate risk is the potential for financial loss caused by fluctuations in fair value or future cash flows of financial instruments because of changes in market interest rates. CHEO is exposed to this risk through its term debt and demand loan.

CHEO mitigates interest rate risk on certain of its debt through derivative financial instruments (interest rate swaps) that exchange the variable rate inherent in the term debt for a fixed rate (see note 11). Therefore, fluctuations in market interest rates would not impact future cash flows and operations relating to the term debt.

(iii) Other price risk:

CHEO believes it is not subject to significant other price risk arising from its financial instruments.

There have been no significant changes from the previous year in the exposure to financial risks or to the policies, procedures and methods used to measure the risks.

18. Ministry of Health pandemic funding:

In connection with the ongoing coronavirus pandemic ("COVID-19), the MOH has announced a number of funding programs intended to assist hospitals with incremental operating and capital costs and revenue decreases resulting from COVID-19. In addition to these funding programs, the MOH is also permitting hospitals to redirect unused funding from certain programs towards COVID-19 costs, revenue losses and other budgetary pressures through a broad-based funding reconciliation.

While the MOH has provided guidance with respect to the maximum amount of funding potentially available to the Hospital, as well as criteria for eligibility and revenue recognition, this guidance continues to evolve and is subject to revision and clarification subsequent to the time of approval of these financial statements. The MOH has also indicated that all funding related to COVID-19 is subject to review and reconciliation, with the potential for adjustments during the subsequent fiscal year.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

18. Ministry of Health pandemic funding (continued):

Management's estimate of MOH revenue for COVID-19 is based on the most recent guidance provided by MOH and the impacts of COVID-19 on the Hospital's operations, revenues and expenses. Management has analyzed the requirements and has provided an estimate for the supportable amounts based on the current available information. Due to the uncertainty of the amount of funding that will be confirmed in future years, management has recorded a provision on the receivable as noted in the chart below. Any adjustments to Management's estimate of MOH revenues will be reflected in the Hospital's financial statements in the year of settlement.

Details of the MOH funding for COVID-19 recognized as revenue in the current year are summarized below:

Funding for incremental COVID-19 operating expenses Funding for revenue losses resulting from COVID-19	\$ 8,919 5,943
Broad-based funding reconciliation for other eligible costs and revenue losses	 - 14,862
Less: Provision for future changes to funding programs	_
	\$ 14,862

In addition to the above, the Hospital has also recognized:

- MOH funding for COVID-19 related capital expenditures in the amount of \$2,354,414, which has been recorded as an addition to deferred capital contributions during the year; and,
- MOH funding in the amount of \$7,490,176 for other COVID-19 related expenditures such as, employee and physician pandemic pay, assessment centers and surgical recovery.

19. Ministry of Health working capital funding:

In March 2021, the Hospital was advised that it was eligible for one-time funding to address its working capital deficit. The Hospital is eligible to receive this funding based on defined eligibility criteria with the stipulation that the funding will only be used to reduce the Hospital's working capital deficit and is not to be used for operating purposes.

As at the date of approval of these financial statements, the MOH has provided its preliminary estimate of working capital funding of \$3,522,600 which has been recognized as revenue. The MOH has indicated that the final amount of funding is subject to further analysis and validation by the MOH. Any future adjustments to this working capital funding will be reflected in the Hospital's financial statements in the year of settlement.

Notes to Financial Statements (continued)

Year ended March 31, 2021 (Tabular amounts in thousands of dollars)

20. COVID-19 impacts:

In March of 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization and has had significant financial, market, health and societal impacts. In response to COVID-19 and consistent with guidance provided by the MOH and other government agencies, the Hospital has implemented a number of measures to protect patients and staff from COVID-19. In addition, the Hospital has actively contributed towards the care of COVID-19 patients and the delivery of programs that protect public health.

Financial statements are required to be adjusted for events occurring between the date of the financial statements and the date of the auditors' report which provide additional evidence relating to conditions that existed at year-end. Management has assessed the financial impacts and there are no additional adjustments required to the financial statements at this time.

The Hospital continues to respond to the pandemic and plans for continued operational and financial impacts during the 2022 fiscal year and beyond. Management has assessed the impact of COVID-19 and believes there are no significant financial issues that compromise its ongoing operations. The outcome and timeframe to a recovery from the current pandemic is highly unpredictable, thus it is not practicable to estimate and disclose its effect on future operations at this time.

21. Comparative information:

Certain comparative information has been reclassified to conform with the financial statement presentation adopted in the current year.

Schedule A - Other funded programs

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

		Revenue		Expenses		2021 Net		Revenue		Expenses		2020 Net
Nouvou				•						•		
MOH/OH:	۴	4 4 0 4	۴	4 4 0 4	۴		۴	4 4 0 4	۴	4 4 0 4	¢	
Clinical Education	\$	1,181	\$	1,181	\$	_	\$	1,181	\$	1,181	\$	—
Municipal Taxes		17		17		_		17		17		_
Special Drug Program		3,134		3,134		—		3,085		3,085		_
FASD Assessment and Diagnostic Services		156		156		-						_
Community Mental Health and Addictions		858		858		-		852		852		-
ECHO		549		549		_		539		539		_
Child and Youth Mental Health		4,909		4,909		_		4,762		4,762		_
Child and Youth Mental Health Pandemic Pay		7		7		_		_		_		-
Centre of Excellence		5,900		5,900		—		5,900		5,900		_
		16,711		16,711		-		16,336		16,336		-
MCCSS programs:												
Adults' DS Community Support Services		586		586		_		502		502		_
Children's DS Community Support Services		2,703		2,703		_		2,787		2,787		_
Infant Development		912		912		_		912		912		_
Early Child Development		6,193		6,193		_		5,030		5,030		_
Out-of-Home Respite		393		393		_		393		393		_
Coordinated Service Planning		1,282		1,282		_		1,237		1,237		_
Physical Rehabilitation		10,095		10,095		_		10,095		10,095		_
Autism Services		19,420		19,420		_		22,902		22,902		_
MCCSS Pandemic Pay		55		55		_		22,302		22,302		
		55		55		_		—		—		_
Healthy Babies Healthy Children - BORN ISCIS		257		257				150		150		
						_						
		41,896		41,896				44,008		44,008		-

Schedule A - Other funded programs (continued)

Year ended March 31, 2021, with comparative information for 2020 (Tabular amounts in thousands of dollars)

	Revenue	Expenses		2021 Net	Revenue		Expenses		2020 Net
Other programs:									
First Words - Pinecrest Queensway	\$ 424	\$	424	\$ _	\$ 424	\$	424	\$	_
Champlain Maternal Newborn Regional Program	871		871	_	857		857		_
Navigator Program	236		236	_	485		485		_
National Newcomer Navigator Program	1,736		1,736	_	1,731		1,731		_
Preschool Program - City of Ottawa	1,079		1,079	_	1,012		1,012		_
Blind/Low Vision Program - Pinecrest Queensway	[´] 39		[´] 39	_	133		[´] 133		_
Preschool SLP - Pinecrest Queensway	1,362		1,362	_	1,362		1,362		_
Canadian Hospitals Injury Reporting and	,		,		,		,		
Prevention Program	113		113	_	114		114		_
Complex Care for Kids Ontario (PCMCH)	368		368	_	_		_		_
Non-Insured Health Benefits (NIHB) Program	2,910		2,910	_	_		_		_
Other Programs	,		,	_	78		78		_
	9,138		9,138	_	6,196		6,196		_
	\$ 67,745	\$	67,745	\$ 	\$ 66,540	\$	66,540	\$	